Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network

Fertility preservation is not only important for malignant diseases but should also be offered to patients with autoimmune diseases (AID) like vasculitides, prior to cyclophosphamide therapy. No recommendations are available for patients with AID. Analysis from the Fertiprotekt registry of all femal...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2012-01, Vol.30 (1 Suppl 70), p.S53-S56
Main Authors: Henes, Joerg C, Henes, Melanie, von Wolff, Michael, Schmalzing, Marc, Kötter, Ina, Lawrenz, Barbara
Format: Article
Language:English
Subjects:
Adult
Counseling
Cryopreservation
Cyclophosphamide - adverse effects
Europe
Female
Fertility - drug effects
Fertility Agents, Female - therapeutic use
Fertility Preservation - methods
Gonadotropin-Releasing Hormone - analogs & derivatives
Gonadotropin-Releasing Hormone - therapeutic use
Humans
Immunosuppressive Agents - adverse effects
Infertility, Female - chemically induced
Infertility, Female - physiopathology
Infertility, Female - therapy
Ovary - transplantation
Ovulation Induction
Parity
Pregnancy
Registries
Vasculitis - drug therapy
Vasculitis - physiopathology
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fertility preservation is not only important for malignant diseases but should also be offered to patients with autoimmune diseases (AID) like vasculitides, prior to cyclophosphamide therapy. No recommendations are available for patients with AID. Analysis from the Fertiprotekt registry of all female patients with age
ISSN:0392-856X